GlassScriptPhysician profile
Cary D Belen
NPI 1982885323
$3,056.40
in general payments reported to CMS, 2019-2025
28 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $134 · 2021: $164 · 2022: $60.04 · 2023: $462 · 2024: $696 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,058 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,057.75 |
| Education | $247.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $354.66 | 2019-2025 | Rayaldee |
| Amgen INC. | $348.68 | 2024-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $342.28 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $304.74 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $266.61 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $190.40 | 2023-2025 | Acthar, Terlivaz |
| Calliditas Therapeutics US INC. | $183.33 | 2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.72 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $150.64 | 2019-2025 | |
| Horizon Therapeutics Plc | $122.80 | 2020-2023 | Krystexxa |
| Ardelyx, INC. | $93.84 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $70.68 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $65.51 | 2024-2025 | Jynarque, Voyxact |
| Glaxosmithkline, LLC. | $63.14 | 2021-2023 | Benlysta, Jesduvroq |
| Takeda Pharmaceuticals U.S.A., INC. | $57.28 | 2019-2024 | Livtencity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $45.24 | 2024-2025 | Defencath, Defencath |
| Travere Therapeutics, INC. | $35.84 | 2024 | |
| Akebia Therapeutics INC | $28.21 | 2025 | Vafseo |
| Novo Nordisk INC | $26.12 | 2025 | Ozempic |
| Lexicon Pharmaceuticals, INC. | $23.95 | 2024 | |
| Alexion Pharmaceuticals, INC. | $20.65 | 2024 | Ultomiris |
| Boston Scientific Corporation | $19.79 | 2023 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Genzyme Corporation | $16.65 | 2019 | |
| Apellis Pharmaceuticals, INC. | $14.17 | 2025 | |
| Daiichi Sankyo INC. | $13.83 | 2024 | Injectafer |
| Arbor Pharmaceuticals, INC. | $11.95 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cary Belen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.